Акции в обращении SinoMab BioScience Limited является 1.006B
Акции в обращении - это все акции корпорации или финансового актива, которые были разрешены, выпущены и приобретены инвесторами и находятся в их собственности.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.